RIVAROXABAN VS. DABIGATRAN OR WARFARIN IN REAL-WORLD OBSERVATIONAL STUDIES OF STROKE PREVENTION IN ATRIAL FIBRILLATION: SYSTEMATIC REVIEW AND META-ANALYSIS
机构：[1]Beijing Tongren Hosp, Beijing, Peoples R China首都医科大学附属北京同仁医院首都医科大学附属同仁医院[2]Guangdong Acad Med Sci, Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China广东省人民医院[3]Univ Birmingham, Inst Cardiovasc Sci, City Hosp, Birmingham, W Midlands, England
第一作者机构：[1]Beijing Tongren Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Bai Ying,Deng Hai,Shantsila Alena,et al.RIVAROXABAN VS. DABIGATRAN OR WARFARIN IN REAL-WORLD OBSERVATIONAL STUDIES OF STROKE PREVENTION IN ATRIAL FIBRILLATION: SYSTEMATIC REVIEW AND META-ANALYSIS[J].HEART.2017,103:A36-A37.doi:10.1136/heartjnl-2017-311726.44.
APA：
Bai, Ying,Deng, Hai,Shantsila, Alena&Lip, Gregory Y. H..(2017).RIVAROXABAN VS. DABIGATRAN OR WARFARIN IN REAL-WORLD OBSERVATIONAL STUDIES OF STROKE PREVENTION IN ATRIAL FIBRILLATION: SYSTEMATIC REVIEW AND META-ANALYSIS.HEART,103,
MLA：
Bai, Ying,et al."RIVAROXABAN VS. DABIGATRAN OR WARFARIN IN REAL-WORLD OBSERVATIONAL STUDIES OF STROKE PREVENTION IN ATRIAL FIBRILLATION: SYSTEMATIC REVIEW AND META-ANALYSIS".HEART 103.(2017):A36-A37
医学